Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LPL | P06858 | 2/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8764230 | 0.87 | MEN1 (0.64) | MEN1KMT2AALDH1A1CA2TSHR | |
| SCHEMBL31324214 | 0.86 | HSD17B10 (0.50) | MEN1KMT2ALPLLIPGALDH1A1 | |
| SCHEMBL10264572 | 0.86 | CYP2A6 (0.54) | MEN1KMT2ALPLLIPGMGLL | |
| SCHEMBL9552354 | 0.83 | HSD17B10 (0.56) | MEN1KMT2ALPLLIPGMGLL | |
| Water SCHEMBL28941509 | 0.82 | LPL (0.59) | LPLLIPGMGLLALDH1A1CA2 | |
| SCHEMBL1016157 | 0.81 | MEN1 (0.52) | MEN1KMT2AALDH1A1MMP9MMP13 | |
| SCHEMBL31258 | 0.81 | LPL (0.45) | MEN1KMT2ALPLLIPGMGLL | |
| SCHEMBL8763175 | 0.80 | MEN1 (0.56) | MEN1KMT2AMGLLALDH1A1TSHR | |
| SCHEMBL9552869 | 0.80 | KMT2A (0.56) | MEN1KMT2AALDH1A1MAPTNPSR1 | |
| SCHEMBL142480 | 0.79 | LPL (0.62) | LPLLIPGMGLLALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4442319-A2 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| EP-4081511-B1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2024-07-31 | — | — | EP | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-0259085-B1 | 2-GUANIDINO-4-ARYLTHIAZOLES FOR TREATMENT OF PEPTIC ULCERS | PFIZER INC. (US) | 1991-08-21 | — | — | EP | disclosed |
| US-5026715-A | 2-guanidino-4-arylthiazoles for treatment of peptic ulcers | PFIZER INC. (US) | 1991-06-25 | — | — | US | disclosed |
| EP-0161841-B1 | 2-(N-SUBSTITUTEGUANIDINO)-4-HETERO-ARYLTHIAZOLE ANTIULCER AGENTS | PFIZER INC. (US) | 1989-07-19 | — | — | EP | disclosed |
| EP-0259085-A1 | 2-Guanidino-4-arylthiazoles for treatment of peptic ulcers | PFIZER INC. (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4560690-A | ANTISECRETORY AGENTS, HISTAMINE H2-ANTAGONISTS | PFIZER INC. (US) | 1985-12-24 | — | — | US | disclosed |
| EP-0161841-A1 | 2-(N-substituteguanidino)-4-hetero-arylthiazole antiulcer agents | PFIZER INC. (US) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | MEN1 4504/4885KMT2A 3125/4885LPL 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.